Key points are not available for this paper at this time.
A cell-active, mutant-specific, covalent inhibitor of KRAS(G12C) is described that targets the GDP-bound, inactive state and prevents subsequent activation. Using this novel compound, we demonstrate that KRAS(G12C) oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.
Building similarity graph...
Analyzing shared references across papers
Loading...
Matthew P. Patricelli
Vividion Therapeutics (United States)
Matthew R. Janes
Wellspring Biosciences (United States)
Lian‐Sheng Li
Wellspring Biosciences (United States)
Cancer Discovery
Wellspring Biosciences (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Patricelli et al. (Wed,) studied this question.
synapsesocial.com/papers/69d96e6234ded318bb684339 — DOI: https://doi.org/10.1158/2159-8290.cd-15-1105
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: